Beijing Strong Biotechnologies,Inc. (SHE:300406)
12.31
-0.37 (-2.92%)
Apr 28, 2026, 3:04 PM CST
SHE:300406 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,371 | 1,356 | 1,648 | 1,737 | 1,508 | 1,598 |
Other Revenue | - | - | 11.28 | 4.4 | 2.88 | 1 |
| 1,371 | 1,356 | 1,659 | 1,742 | 1,511 | 1,599 | |
Revenue Growth (YoY) | -13.52% | -18.29% | -4.75% | 15.27% | -5.53% | 88.58% |
Cost of Revenue | 279.12 | 279.92 | 361.88 | 445.01 | 384.12 | 448.5 |
Gross Profit | 1,091 | 1,076 | 1,297 | 1,297 | 1,127 | 1,151 |
Selling, General & Admin | 405.35 | 408.88 | 457.67 | 491.04 | 457.36 | 444.38 |
Research & Development | 179.28 | 181.73 | 188.53 | 162.9 | 137.2 | 127.01 |
Other Operating Expenses | 9.61 | 10.19 | 15.45 | 14.97 | 12.85 | 12.92 |
Operating Expenses | 594.23 | 600.81 | 665.03 | 692.35 | 625.46 | 602.71 |
Operating Income | 497.16 | 474.78 | 632.01 | 604.27 | 501.29 | 548.17 |
Interest Expense | - | - | -47.61 | -46.99 | -52.64 | -21.59 |
Interest & Investment Income | 15.8 | 12.14 | 19.82 | 25.95 | 21.48 | 15.74 |
Currency Exchange Gain (Loss) | - | - | -0.1 | -0.12 | 2.21 | -0.29 |
Other Non Operating Income (Expenses) | -67.94 | -67.03 | 2.39 | -3.5 | -28.33 | -19.94 |
EBT Excluding Unusual Items | 445.01 | 419.88 | 606.52 | 579.62 | 444.01 | 522.09 |
Impairment of Goodwill | - | - | - | - | -3.03 | - |
Gain (Loss) on Sale of Investments | 0.15 | - | - | - | - | - |
Gain (Loss) on Sale of Assets | -2.2 | -2.87 | -2.11 | -3.5 | -2.68 | 0.16 |
Asset Writedown | -180.76 | -180.76 | -1.38 | -0.21 | -2.29 | -0.11 |
Other Unusual Items | - | - | 17.66 | 17.64 | 13.35 | 14.85 |
Pretax Income | 262.21 | 236.25 | 620.69 | 593.55 | 449.35 | 536.99 |
Income Tax Expense | 49.64 | 45.71 | 89.53 | 71.48 | 54.89 | 67.33 |
Earnings From Continuing Operations | 212.58 | 190.54 | 531.16 | 522.07 | 394.46 | 469.66 |
Minority Interest in Earnings | -0.35 | -0.66 | 1.47 | 1.67 | -5.37 | -64.01 |
Net Income | 212.22 | 189.87 | 532.64 | 523.74 | 389.1 | 405.65 |
Net Income to Common | 212.22 | 189.87 | 532.64 | 523.74 | 389.1 | 405.65 |
Net Income Growth | -57.63% | -64.35% | 1.70% | 34.60% | -4.08% | 261.30% |
Shares Outstanding (Basic) | 591 | 593 | 579 | 582 | 581 | 588 |
Shares Outstanding (Diluted) | 591 | 593 | 592 | 595 | 614 | 588 |
Shares Change (YoY) | -1.95% | 0.26% | -0.56% | -3.00% | 4.37% | 7.25% |
EPS (Basic) | 0.36 | 0.32 | 0.92 | 0.90 | 0.67 | 0.69 |
EPS (Diluted) | 0.36 | 0.32 | 0.90 | 0.88 | 0.67 | 0.69 |
EPS Growth | -56.79% | -64.44% | 2.27% | 31.47% | -2.99% | 236.88% |
Free Cash Flow | 558.46 | 525.87 | 546.36 | 437.06 | 299.69 | 275.9 |
Free Cash Flow Per Share | 0.94 | 0.89 | 0.92 | 0.73 | 0.49 | 0.47 |
Dividend Per Share | - | - | 0.400 | 0.200 | 0.100 | 0.100 |
Dividend Growth | - | - | 100.00% | 100.00% | - | 0.66% |
Gross Margin | 79.63% | 79.35% | 78.19% | 74.45% | 74.58% | 71.96% |
Operating Margin | 36.27% | 35.03% | 38.10% | 34.70% | 33.18% | 34.27% |
Profit Margin | 15.48% | 14.01% | 32.11% | 30.07% | 25.75% | 25.36% |
Free Cash Flow Margin | 40.75% | 38.80% | 32.93% | 25.09% | 19.84% | 17.25% |
EBITDA | 567.6 | 544.87 | 700.68 | 658.03 | 554.35 | 590.51 |
EBITDA Margin | 41.41% | 40.20% | 42.24% | 37.78% | 36.69% | 36.92% |
D&A For EBITDA | 70.45 | 70.09 | 68.67 | 53.76 | 53.05 | 42.33 |
EBIT | 497.16 | 474.78 | 632.01 | 604.27 | 501.29 | 548.17 |
EBIT Margin | 36.27% | 35.03% | 38.10% | 34.70% | 33.18% | 34.27% |
Effective Tax Rate | 18.93% | 19.35% | 14.42% | 12.04% | 12.22% | 12.54% |
Revenue as Reported | - | - | 1,659 | 1,742 | - | 1,599 |
Advertising Expenses | - | - | 153.01 | 194.01 | 200.07 | 186.98 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.